Chapter 4: Pharmacogenetics & Personalized Drug Therapy

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today we are tackling a subject that really fundamentally changes the way we look at medicine.

It really does.

You know, we often have this idea, maybe it's a subconscious thing, that a pill is a pill.

You take Tylenol, I take Tylenol, and it does the exact same thing to both of us.

Right.

It's a comforting thought, isn't it?

It's very comforting, yeah.

The idea that medicine is standardized.

But if you look at the research, specifically chapter four of pharmacology, a patient -centered nursing process approach,

that assumption isn't just slightly off.

Oh, no.

It is dangerously wrong.

It is remarkably wrong.

And, you know, recognizing just how wrong it is forms the basis of what we call pharmacogenetics.

This isn't just about some people handle caffeine better than others.

This is about why a standard dose of a life -saving drug might cure one person and send another person to the morgue.

That is a heavy way to open, but I think the text absolutely warrants it.

It does.

To set the scene for everyone listening, I want you to visualize the opening graphic from the chapter.

It's this illustration of a crowd of people.

Yeah, I remember that one.

You've got people in blue shirts, purple shirts, all standing together, and the caption is simply, one size does not fit all.

Right.

It looks like a marketing slogan, but in this context, it's a warning label.

It is absolutely a warning label.

The mission for this deep dive is to unpack chapter four, pharmacogenetics.

We are speaking directly to the nursing students out there.

Yes.

Our goal is to help you master this content, not just so you can pass an exam, but because this is the future of safety and clinical practice.

This is about preventing tragedy at the bedside.

So here's the roadmap for today.

We aren't just going to list definitions.

We are going to go on a bit of a journey.

We start with the problem, the trial layer method that we currently use.

Then we're going to look at the history, because you can't really understand where we are without seeing where we came from.

That's right.

After that, we're getting into the engine room, the liver enzymes and drug metabolism.

That is the core mechanism.

I mean, if you don't understand the metabolism, the rest is just memorizing lists.

We need to understand the why.

Precisely.

Then we'll review the specific must -know drugs.

We're talking about the ones that are likely to show up on your boards, and more importantly - The ones that really hurt people.

The ones that kill patients, if you get them wrong.

Then we have to talk about the legal and

genetic privacy justice.

Which is huge.

And finally, we will wrap it all up with the nursing process and the clinical judgment case study involving a patient who just can't get pain relief.

It sounds like a mountain of information, but it flows very logically.

It does.

It's the story of how we move from guessing to knowing.

Let's start with that guessing part, because right now the text describes the current standard of prescribing as, well, trial and error.

That feels incredibly primitive for 21st century medicine.

It does feel primitive, doesn't it?

If you look at the diagrams in the chapter, they illustrate the current workflow.

A provider looks at a patient and prescribes based on the basics.

Age, weight,

sex, maybe?

Organ function?

Maybe liver and kidney function?

Which makes sense.

I mean, if I'm 200 pounds, I might need more than someone who is 100 pounds.

It makes sense on the surface, but it's incomplete.

It's a statistical guess.

It's based on the average human.

But no one is actually average.

But no single patient is actually the average human.

And the statistics on how often that guess is wrong are actually quite staggering.

The text notes that nearly 50 % of people stop taking their prescribed medications.

Stop there for a second.

50%.

It's 50.

Five zero.

That implies that for every two scripts written, one is eventually thrown in the trash or just left in the cabinet.

Essentially, yes.

And we have to ask why.

The reasons aren't usually defiance.

It's either side effects that are too difficult to manage, the drug makes them feel terrible, or the drug simply didn't work.

It failed.

That is a massive number.

I mean, imagine if half the time you bought a car, it just didn't start.

You'd never buy that car again.

Or half the time you bought a sandwich gave you food poisoning.

We wouldn't accept that in any other industry.

And the consequences here are so much more severe than a bad sandwich.

Patients often try up to four different drugs before finding the right one.

Think about the time lost there.

Think about the suffering while you wait for the fourth drug to finally work.

And the cost.

Financially, the annual cost of treatment failure is over $2 ,500 per patient.

But the really scary number, the one that should make every nursing student sit up straight, is the mortality rate.

Adverse drug reactions cause over 125 ,000 deaths annually.

125 ,000 deaths.

That's a medium -sized city, wiped out every single year just because we gave them the standard dose.

It's terrifying.

That's terrifying.

It's an epidemic in itself.

And if you look at emergency department visits, it's nearly one million annually, costing the health care system about $3 .5 billion.

And the text lists the top offenders for these ED visits.

What are we seeing there?

Is it weird, obscure drugs?

No, it's the heavy hitters.

It's the stuff you see every day on the med cart.

Like what?

Anticoagulants, antibiotics, diabetes drugs, and opioid analgesics.

They're the most common ones.

These are the drug classes most likely to land someone in the hospital due to an adverse reaction.

So we have this system of trial and error that is costing billions and killing people.

The solution, according to this chapter, is precision medicine.

But that sounds like a buzzword.

What does it actually mean?

It means pharmacogenetics.

The definition provided is the study of how a patient's genetic factors influence their response to drugs.

Instead of treating the average human, we treat the specific code inside the person in front of us.

And the goal seems pretty straightforward.

Individualize the treatment.

Right.

Optimize the therapy.

Decrease those adverse reactions we just talked about.

Promote adherence.

Because if the drug works and doesn't make you sick, you'll actually keep taking it.

Which is that 50 % problem.

Which helps with that 50 % problem and ultimately reduce costs.

There is actually a legislative context to this too, right?

The text mentions HR 6875.

Yes.

The Right Drug Dose Now Act, introduced in 2022.

It's interesting because it shows the political will to fix this.

So people are paying attention.

They are.

The bill proposed funding to educate healthcare providers about pharmacogenomics and, crucially, to integrate this data into electronic health records or EHRs.

That integration seems key.

It doesn't help if the genetic info is in a filing cabinet somewhere.

Not at all.

It needs to be on the screen when the doctor is prescribing.

It needs to flash read and say, don't give this.

Precisely.

It needs to be part of the clinical decision support system, a safety net.

Okay.

Let's sit back and look at the history here.

Right.

Because while this feels very futuristic, you know, DNA swabs and computer warnings, the roots go back a long, long way.

They do.

The timeline really starts in 1865 with Gregor Mendel.

The mooc with the pea plants.

I remember this from high school biology.

It's the very same.

He was the first to explain dominant versus recessive genes.

The text shows the classic Punnett Square, you know, big B for brown eyes, little B for blue eyes.

Right.

That logic is the foundation of everything we are discussing today.

He figured out that traits are passed down in specific, predictable packages.

But he didn't know about DNA, right?

He just called them factors.

Correct.

He had no idea what the mechanism was.

It wasn't until 1953 that Watson and Crick discovered the double helix structure of DNA.

That unlocked the physical mechanism.

Yes.

Suddenly we knew what the package looked like.

We could see the ladder.

And then the big one, the Human Genome Project.

The moon landing of biology completed in 2003.

They mapped roughly 25 ,000 genes in human DNA.

They read the whole book.

They read the entire instruction manual for a human being.

It's amazing to think that was only about 20 years ago.

In the grand scheme of medicine, that's just yesterday.

It is.

And then in 2015, the Precision Medicine Initiative launched.

The goal there was to expand treatment by considering genes, environment, and lifestyle, as the text says.

The right patient?

Treating the right patient with the right drug at the right dose.

Now, before we go further into the weeds, we need to clarify some terminology.

Table 4 .1 breaks this down, and I think this is where students can get tripped up.

Yeah, these words sound very similar.

There's pharmacogenetics and pharmacogenomics.

Are they the same thing?

They sound identical.

They are often used interchangeably in clinical practice, and the text notes that, so don't get too stressed about it.

But there is a subtle academic difference.

Pharmacogenetics generally refers to the study of variability in drug response due to heredity, usually focusing on a single gene interaction.

So like, how does this one gene affect this one drug?

Exactly.

It's more targeted.

And pharmacogenomics?

Pharmacogenomics is broader.

It's the combination of pharmacology and genomics, looking at the whole genome and the environment to develop effective medications.

It's the big picture.

So genetics is more one gene, one drug, and genomics is the whole system.

That's a safe way to think about it for an exam.

Okay, next term.

Allel.

This feels like a vocab quiz, but we need these bricks to build the house.

We do.

An allele is simply a version of a gene.

You inherit two alleles for each gene, one from mom, one from dad.

If they are the same, you are homozygous.

If they are different, you are heterozygous.

And polymorphisms.

That's a $10 word.

It sounds intimidating, but it just means many forms.

These are natural variations in a gene that occur frequently in the general population.

They aren't necessarily mutations in the scary sci -fi sense, like X -Men or a tumor.

So not a defect.

Not a defect.

They are just common variations that make us different.

Like having blue eyes instead of brown.

But instead of eye color, it changes how your liver works.

Which brings us to the engine room.

The metabolizer classes.

This to me seems like the most critical concept in the entire chapter for a nursing student.

I agree.

If you don't get this, you don't get safety.

Absolutely.

If you take nothing else away from the basic science section, take this.

This explains how patients react.

And it all revolves around the cytochrome P450 system.

The liver enzymes.

The CYP enzymes.

The CYP enzymes.

Think of these enzymes as workers on an assembly line.

Their job is to break down drugs.

Okay.

So we have four categories of these workers.

Let's walk through them.

First, the extensive metabolizers.

This is your baseline.

You're normal.

An extensive metabolizer has an ordinary standard response to drugs.

They have two functioning alleles.

So the workers show up on time.

The workers show up on time and do the job at the standard speed.

The standard dose on the bottle is designed for them.

Okay.

So if the bottle says take 500 milligrams, it assumes you are an extensive metabolizer.

Correct.

That's the default assumption for everyone.

Next is intermediate metabolizers.

These individuals have decreased efficiency.

Maybe one allele works and the other doesn't.

Or they have a variant that just works slower.

The workers are a bit sluggish.

The result is that they break down the drug slower than normal.

This leads to a higher concentration of the parent drug in their system.

Which implies a risk of side effects.

Yes.

Think of it like a bathtub drain.

If the drain is partially clogged, which is an intermediate metabolizer, the water, which is the drug, drains slower.

The tub fills up higher than you expect.

Got it.

Then we have poor metabolizers.

This is a significant decrease in drug metabolism.

The drain is almost totally clogged.

Oh, wow.

They will have very high levels of the parent drug because the body isn't clearing it.

This carries a high risk of adverse response and often very little therapeutic benefit because the drug is just sitting there causing toxicity.

So for a standard drug, a poor metabolizer is basically at risk of an overdose.

Even on a completely normal dose.

Exactly.

You give them a standard pill and their body treats it like a double or triple dose because it just won't leave.

And finally, the ultra rapid metabolizers.

The opposite problem.

Their efficiency is increased.

The drain is wide open.

They metabolize the drug too fast.

So for a standard drug, it would just wash out of their system before it does anything.

Exactly.

Possible decrease in effectiveness.

You give them a painkiller and their liver shreds it before it can reach the brain.

They get no relief.

Okay.

So that's the rule for a standard drug.

Poor metabolizer equals toxicity.

Ultra rapid equals failure.

But.

And here's where it gets tricky.

Yes.

Not all drugs are standard.

This is the pro drug trap.

And this is where students fail exams and where patients get hurt.

Let's hold on the pro drug explanation for just a moment until we get to the specific drugs because I want to map that out carefully.

Good idea.

Before we get there, let's talk about the process.

Who actually gets this testing?

Because I assume we aren't swabbing every single person who walks into a clinic for a headache.

No, not yet anyway.

And table 4 .3 gives us a decision making process.

It's not appropriate for everyone yet due to cost and availability.

So where are the priority patients?

The patients who benefit most are those on multiple drugs.

Polypharmacy is a big trigger.

Also, patients with complex treatment regimens or those who are simply not responding to current therapy.

The mystery patients.

Yeah.

The ones where the doctor scratches their head and says, why isn't this working?

Right.

Or patients who have had previous adverse reactions.

And of course, there is a specific list of drugs that have pharmacogenetic information right in their boxed warnings.

So it's required reading.

If you are prescribing abacovir or warfarin, you are prioritizing this testing.

You have to.

The text outlines a process model in figure 4 .5.

Can you walk us through that workflow?

Imagine I'm a nurse in a clinic.

How does this go down?

Sure.

It starts with step one, intention.

The provider identifies a patient.

Maybe they are multi -morbid or starting a high -risk drug.

Step two is the genetic analysis.

This is usually a DNA swab, often a buckle or cheek swab.

It's painless, non -invasive.

And step three is the report.

This is where the decision support comes in.

You get a report saying,

patient is a CYP2C19 poor metabolizer.

It interprets the raw data for you.

So it's not just a bunch of letters.

No, it gives a clinical recommendation, which leads to step four, the prescribing change.

You adjust the dose or switch the drug entirely based on that report.

And step five.

Step five is the outcome.

Hopefully, a reduction in adverse events and a better therapeutic effect.

It seems like a very clean loop.

Test, decide, treat.

In theory, yes.

In practice, challenges remain, like turnaround time.

You might need the drug now, but the test takes days and insurance coverage.

But that is the model we are striving for.

All right.

Let's get into the specifics.

The text provides a list of specific drugs that have genetic implications.

I feel like for a nursing student, these are the flash card items.

They are.

These are the ones you need to memorize.

But more than that, we need to understand the mechanism.

Absolutely.

Don't just memorize the name, understand the mechanism, and you'll remember it forever.

Let's start with abacavir.

This is an HIV treatment.

Yes.

Abacavir is a critical antiretroviral, but it has a dark side.

The risk here is a fatal multi -organ hypersensitivity reaction.

Fatal.

It affects about 6%, 10 % of patients.

Hypersensitivity sounds like an allergy, like a rash.

But you said fatal.

It's not just a rash.

Imagine the immune system as a bouncer at a club.

For most people, abacavir enters the club, does its job, and the bouncer ignores it.

But for people with a specific gene, HLAB5701, that gene acts like a wanted poster.

It tells the bouncer, if you see abacavir, burn the club down.

Wow.

So the immune system attacks the drug and the body.

It triggers a massive systemic inflammatory storm fever, rash, organ failure.

It's an immune revolt.

And the gene is HLAB5701.

Correct.

The FDA recommendation is strict.

You must screen for HLAB5701 before starting therapy.

Before the first dose.

Before the first dose.

If they are positive, you do not give the drug.

Period.

It is an absolute contraindication.

Okay.

That's very clear.

Next is warfarin.

We see this all the time in hospitals.

Warfarin is an anticoagulant of vitamin K antagonist.

It already has a very narrow therapeutic range, meaning the difference between a working dose and a dangerous dose is razor thin.

And the risk is bleeding.

Life -threatening bleeding.

The genes involved here are CYP2C9 and VKORC1.

Two genes.

Yes.

Think of it like a car.

CYP2C9 is the mechanic that removes the warfarin from the body.

It's the metabolism part.

The drain.

The drain.

If that mechanic is slow a variant allele, the warfarin builds up.

VKORC1 controls how sensitive the engine is to the fuel.

So that's the pharmacodynamics.

Exactly.

Some people are just naturally more sensitive to the drugs effects.

So if you have a slow mechanic, a clogged drain, and a super sensitive engine.

A standard dose will cause massive internal bleeding.

The labeling for warfarin actually contains dosing tables based on these genotypes.

So a nurse needs to be watching for that.

A nurse administering warfarin needs to be hyper aware of bleeding signs, gums, bruising, blood, and stool, especially if genetic status is unknown.

Okay, now let's talk about clopidogrel.

This is the one where the metabolizer logic gets a little inception -like.

Yes.

This is the pro -drug trap.

This is the most important concept to grasp.

Clopidogrel is an inhibitor of platelet aggregation.

It's used to prevent heart attacks and strokes.

But, and this is the key, it is a pro -drug.

We need a really good analogy here.

Right.

What is a pro -drug?

Okay, think of a pro -drug like a hand grenade.

Okay.

When you hold a grenade, it's harmless.

It's a paperweight.

It is inactive.

To make it work, you have to pull the pin.

Okay, so the pill in the bottle is the grenade with the pin in.

Exactly.

When you swallow it, it goes to the liver.

The liver enzyme, specifically CYP2C19, is the soldier.

The soldier's job is to pull the pin.

The enzyme pulls the pin?

Once the pin is pulled, the drug becomes the active metabolite and goes off to stop platelets from clumping.

Okay, I'm with you.

The liver enzyme activates the drug.

It's not breaking down for removal.

It is activating it.

So let's apply the metabolizer classes.

If you are a poor metabolizer of CYP2C19, you don't have enough soldiers.

You swallow the grenade and nobody pulls the pin.

So the grenade stays a paperweight.

Exactly.

It stays inactive.

It does nothing.

So usually, poor metabolizer means toxic overdoser because the trash isn't taken out.

Right.

But for a pro -drug, poor metabolizer means therapeutic failure.

You nailed it.

That is the critical thinking piece.

The clinical consequence is that the patient is taking the pill, thinking they are protected from clots, but they aren't.

And they have a heart attack anyway.

They form a clot, have a stroke, or a heart attack.

That is huge.

So if I'm a nurse and I see a patient on clopidogrel who comes back with a stroke,

my first thought shouldn't just be bad luck.

It should be did the drug even work?

Precisely.

And testing is available for this.

A buckle swab can check for CYP2C19 variants.

This logic applies to opioids too, right?

Right.

Specifically, codeine and tramadol.

Yes.

These are also pro -drugs.

They require the enzyme CYP2D6 to convert into their active forms.

Okay.

Codeine, for example, is actually converted into morphine in the liver.

That's how it gives pain relief.

So if I'm a poor metabolizer of CYP2D6...

You take the codeine, but your liver can't turn it into morphine.

I have no soldiers.

You have no soldiers to pull the pin.

You get zero pain relief.

This must be so frustrating for patients.

They are in pain.

They take the pill.

It doesn't work.

And the nurse or doctor might think they are drug seeking.

Absolutely.

I took it and it didn't help.

I need more.

Yeah.

It is a classic setup for bias and misunderstanding.

The patient says it's not working.

The provider suspects addiction or tolerance.

But the reality is biology.

The enzyme isn't there.

Now, what about the flip side for opioids?

The ultra -rapid metabolizers.

This is where the grenade analogy gets scary.

If you are an ultra -rapid metabolizer of CYP2D6, you have too many soldiers pulling pins.

You convert the codeine to morphine too fast.

You get a massive spike of morphine all at once.

Yes.

Even on a standard dose.

This leads to toxicity, severe sedation, and respiratory depression.

Wow.

There have been tragic cases of children dying after routine surgeries like tonsillectomies because they were given codeine and happened to be ultra -rapid metabolizers.

That is heartbreaking.

And completely preventable.

Completely preventable.

Are there demographic considerations here?

Yes.

The text notes that white individuals and people of Asian and Middle Eastern descent are most likely to have these specific variants.

It's something to keep in mind during assessment.

Okay.

Let's look at mental health drugs.

This feels like an area where trial and error is the absolute norm.

Try this antidepressant for six weeks.

If it doesn't work, we'll try this one.

It is, and it's agonizing for patients.

Many antidepressants and antipsychotics are metabolized by CYP2D6, the same one as opioids.

Interesting.

Drugs like aripiprazole, which is for bipolar and schizophrenia, and atomoxetine for ADHD.

What are the risks here?

Are they pro drugs?

Mostly they're standard drugs, so the standard logic applies.

The bathtub drain analogy.

Okay.

Slow metabolism, the poor metabolizers, leads to toxic concentrations, more side effects, more sedation, more dizziness.

Fast metabolism leads to subtherapeutic levels.

The drug doesn't help the depression or psychosis.

There's a specific note about citilacram, an SSRI.

Yes, citilacram is metabolized by CYP2C19.

Poor metabolizers risk QT prolongation.

QT prolongation, that's a heart rhythm issue.

Yes, it predisposes the patient to a fatal arrhythmia called torsades de points.

Okay.

Because of this genetic risk, there is a maximum dose cap of 20 milligrams per day for these patients.

If you see a poor metabolizer on 40 milligrams of citilprim, that is a red flag.

That's a medication they're waiting to happen.

That's a call to the provider.

Moving to carbamazepine.

This is used for seizures and mood stabilization.

The gene here is HLAB1502.

Another HLA1, so another bouncer situation.

Exactly.

The immune system again.

The risk is severe skin reactions, Stevens -Johnson syndrome, SJS or toxic epidermal necrolysis TNN.

Describe SJS for the students.

It's not just a rash.

No, it's horrific.

The skin blisters and peels off in sheets.

It affects the mucous membranes, eyes, mouth, genitals.

It's like a burn victim.

It is absolutely life -threatening.

And who is at risk?

Persons of Asian descent are most likely to carry this variant.

Screening is very important in this population.

If you have a patient of Asian descent starting carbamazepine, you need to check if this test has been done.

Two more on the list, mercaptopurine.

This one is used for leukemia.

The genes are TPMT and NUDT15.

Genetic variation interferes with metabolism.

If you are a poor metabolizer, the drug destroys the bone marrow.

You get severe myelosuppression and infection.

Just massive toxicity.

A completely predictable and preventable toxicity.

And finally, ear no -tickin.

Used for colon cancer.

The gene is UGT1A1.

Variations lead to an inability to eliminate the drug.

The result is severe diarrhea and severe neutropenia.

Again, life -threatening infection.

Life -threatening infection.

That is quite a list.

But you can see the pattern.

It's all about either the drug building up to toxic levels, our clogged drain, or not converting to the active form, the pro -drug with the missing soldier.

Exactly.

If you understand the mechanism drain versus soldier, you don't just have to memorize the list.

You can predict the outcome.

Let's shift gears to the legal and ethical issues.

Because whenever we talk about genetics, we are talking about very personal data.

This isn't just a cholesterol number.

Yeah.

This is your code.

The text frames this around three pillars.

Privacy, autonomy, and justice.

Let's start with privacy.

The big questions are, who owns the data?

Who has access to it?

If I find out I have a gene that makes me risky to insure, or does my insurance company get to know, is there a risk of labeling?

And autonomy.

This is the patient's right to consent or refuse.

A patient has the right to say, no, I don't want to know my genetic makeup.

And you have to respect that.

You have to.

Maybe they don't want to know they are at risk for something scary.

And they have the right to change their mind.

And justice.

This feels like the biggest societal hurdle.

This is about equal and fair treatment.

There is a real risk of genetic profiling or denial of treatment based on race or ethnicity if testing isn't available to everyone.

Right.

We have to ensure that we don't have a system where only wealthy patients get precision medicine while everyone else gets trial and error.

To address some of these fears, Congress passed GINA.

The Genetic Information Nondiscrimination Act of 2008.

What does GINA actually do?

It prohibits health insurers and employers from discriminating based on genetic information.

So your health insurance can't drop you or raise your premiums because you have a gene for breast cancer or a CYP2D6 variants.

And your boss can't fire you.

And your boss can't fire you for it.

It sounds good.

It sounds comprehensive.

It sounds comprehensive, but the text highlights some crucial limitations.

And nurses need to know these because patients will ask, if I take this test, will it hurt me?

So where are the holes in GINA?

GINA does not cover everything.

It does not extend to life insurance, disability insurance, or long -term care insurance.

Oh, wow.

So if I get tested and it shows a high risk for a future disease,

my life insurance premiums could double.

Or they could deny you coverage entirely.

They could just say no.

Yes.

That is a real possibility.

So if a young father is thinking about genetic testing, he needs to know that this might affect his ability to get life insurance for his family.

That is a massive loophole.

Also, GINA does not apply to members of the military, the Veterans Health Administration, or the Indian Health Services.

They have different regulations.

So you cannot promise total protection.

So bringing this all back to the bedside, let's talk about the nursing process.

We've learned the science, the drugs, the laws.

Now, I'm standing in the room with the patient.

What do I do?

The overarching concept is safety.

Start with assessment.

What are we looking for?

Family history is key.

The text says to go back three generations.

You aren't just asking, does your dad have diabetes?

You are asking, has anyone in your family ever had a bad reaction to a drug?

Oh, that's a great question.

Did anyone die suddenly from a medication?

Treatment failures in the family.

Right.

Did your mother take Tylenol with codeine and get sick?

Did she say it didn't work?

That's a clue for a CYP2D6 variance.

OK.

Also, assess the patient's understanding.

Are they scared of genetic testing?

Determine their ethnicity, as we've seen how relevant that is for drugs like carbamazepine and codeine.

Analysis and planning seem to focus on anxiety and coping.

Yes.

Genetic information can be anxiety -inducing.

My genes are broken.

I'm a mutant.

We need to plan for education and support.

Integrate their preferences, values, and traditions.

And implementation.

Taking action.

Refer to genetic counseling if needed.

That's a specialized role.

But a big practical tip for nurses.

Teach patients to report their genetic findings to all their providers.

Right.

Don't assume the cardiologist knows what the oncologist found.

The systems don't always talk to each other.

Exactly.

The EHRs are getting better, but they aren't perfect.

Avoid duplicate testing.

Also, encourage behavior changes.

The text makes a beautiful point here.

Medical conditions are a fusion of life choices,

environment, and genetics.

It's not just destiny.

It's not just the genes.

Changing the environment can help.

Finally, evaluation.

Did it work?

Did the intervention improve the outcome?

Did the genetic test lead to a drug switch that stopped the pain or stopped the bleeding?

It's closing the loop.

Let's make this real with the clinical judgment case study provided in the chapter.

Let's walk through it.

This is a classic scenario.

We have a patient with a vertebral fracture.

Very painful.

They are prescribed tramadol.

Tramadol is an opioid.

It's one of those pro drugs we talked about, a grenade.

Correct.

The patient takes 100 milligrams every six hours.

And after 24 hours.

No relief.

The pain is still eight out of 10.

So the provider, following standard trial and error logic, bumps the dose up.

150 milligrams every four hours.

And still no relief.

So using our pharmacogenetics knowledge, let's analyze the why.

Why is this woman in agony despite taking massive doses of painkillers?

Question one.

Which liver enzyme converts tramadol?

We know this.

It's CYP2D6.

Tramadol is a grenade.

It needs a pin puller.

Question two.

Which polymorphism is suspected?

Since the patient is getting no relief even at high doses, they are likely a poor metabolizer.

No soldiers.

They lack the functioning enzyme.

They have no soldiers to pull the pins.

And the outcome.

They cannot convert the inactive pro drug to the active metabolite.

The result is no pain relief.

And the danger here is that if the doctor keeps increasing the dose, thinking they just need more, they are loading the patient with the parent drug, which might have other side effects, without treating the pain.

Exactly.

The solution isn't more drug.

It's a different drug.

One that doesn't rely on CYP2D6, maybe morphine directly or a different class entirely.

That really crystallizes why this matters.

It prevents suffering.

It stops us from treating patients like drug seekers when they're actually just poor metabolizers.

It does.

It changes nursing from monitoring for side effects to preventing them before they happen.

It empowers you to be an advocate.

All right.

We have covered a mountain of information.

Let's do a quick fire review quiz to see if our listeners were paying attention.

Let's do it.

I'm going to throw questions at you.

Question one.

What class of drug is clopidogrel?

And what happens if you are a poor metabolizer?

It is an inhibitor of platelet aggregation.

It is a pro drug.

If you are a core metabolizer, you cannot activate it.

You are at risk for clotting, stroke, or a heart attack.

Question two.

HIV patients need testing for HLA -B5701 before taking what drug?

Abacavir to prevent that fatal bouncer hypersensitivity reaction.

Question three.

If a patient has a TPMT deficiency, what should happen to their mercaptopurine dose?

The dose should be decreased.

They can't metabolize it.

That's the clogged drain.

So a normal dose would be toxic.

Perfect.

You know, looking at all of this, the final takeaway for me is that sentence you mentioned earlier.

The future is right drug, right dose, right patient.

It is.

We are moving away from the statistical average and toward the individual.

But we must always remember, as the text concludes, that medical conditions are that fusion life choices, environment, and genetics.

Right.

We treat the whole person, not just the allele.

That is a perfect place to leave it.

Thank you so much for joining us on this deep dive into pharmacogenetics.

My pleasure.

And to our listeners, thank you for your time.

This has been the Last Minute Lecture Team, helping you study smarter, not harder.

Good luck with your exams.